Harold Nathan Tan

Modernizing renal eligibility in oncology trials

Harold Nathan Tan, Sreedhar Mandayam, Prabir Roy-Chaudhury, Timothy A. Yap

The selection of appropriate eligibility criteria is a cornerstone of early phase clinical trial design. The objective assessment of renal function is especially critical, as a significant proportion of investigational agents undergo renal elimination. Impaired renal function can result in systemic drug …

us (code pays fourni par la source)

Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors

Harold Nathan Tan, Hung Le, Khaoula Ben Haj Frej, Lei Kang et autres

Thymic carcinoma, thymoma, and thymic neuroendocrine tumors are rare malignancies with limited treatment options in advanced stages. Immune checkpoint inhibitors (ICIs) have shown preliminary activity in thymic tumors, although their clinical benefit and toxicity profile remain incompletely defined. We retrospectively analyzed patients …

us (code pays fourni par la source)

Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity

Carlos Torrado, Clark R. Andersen, Lei Kang, Amanda L. Brink et autres

BACKGROUND: Telemedicine expanded rapidly during the COVID-19 pandemic, but its role in early-phase oncology trials remains uncertain. We evaluated its impact on recruitment, enrollment, equity, and access in a large phase I program. PATIENTS AND METHODS: We retrospectively analyzed patients seen for …

us (code pays fourni par la source)

Targeting DNA damage response pathways in cancer

Carlos Torrado, Harold Nathan Tan, Timothy A. Yap

us (code pays fourni par la source)

Circulating tumor DNA as a biomarker in early phase clinical trials

Harold Nathan Tan, Mitchell J. Elliott, Ian M. Silverman, Lillian L. Siu et autres

us, ca (code pays fourni par la source)

Abstract B084: Clinical Outcomes and Biomarker Correlates of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Novel Immunotherapies in Phase 1 Trials

Harold Nathan Tan, Timothy A. Yap, Jordi Rodón, Bettzy Stephen et autres

Abstract Introduction Immune checkpoint inhibitors (ICIs) have transformed head and neck squamous cell carcinoma (HNSCC) treatment, yet most patients (pts) eventually progress. There is a need for novel immunotherapy (IO) strategies beyond checkpoint blockade. Investigational agents are being tested in early-phase trials, …

us (code pays fourni par la source)

Drugging the DNA damage response in the clinic: going beyond PARP

Álvaro González-Ortiz, Camila Bragança Xavier, Harold Nathan Tan, Natalie Y.L. Ngoi et autres

Introduction Targeting the DNA damage response (DDR) has emerged as a promising therapeutic strategy in oncology. This review highlights the growing clinical relevance of DDR inhibitors beyond PARP inhibitors, focusing on novel targets, biomarker-driven patient selection, and rational combination strategies.Areas Covered A …

us, es, sg, fr (code pays fourni par la source)

986P Phase I study of NovoTTF-100L(P) in combination with chemotherapy in patients with predominant hepatic metastatic colorectal cancer

Siqing Fu, Harold Nathan Tan, Jordi Rodón, Ecaterina E. Dumbrava et autres

us (code pays fourni par la source)

Treatment-related adverse events of antibody drug-conjugates in clinical trials

Harold Nathan Tan, Marta Ascanio Morcillo, Juanita Lopez, Anna Minchom et autres

BACKGROUND: Antibody-drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a decade and pivotal phase …

gb, us (code pays fourni par la source)

Association of immune-related adverse events with survival and treatment outcomes in thymic tumors treated with immune checkpoint inhibitors.

Harold Nathan Tan, Khaoula Ben Haj Frej, Lei Kang, Hung V. Le et autres

8111 Background: Thymic tumors are rare cancers with limited therapeutic options, particularly in refractory cases. Immune checkpoint inhibitors (ICIs) such as anti-PD1 and anti-PD-L1 antibodies have transformed cancer treatment, but data in thymic tumors remain scarce. We investigated the safety, efficacy, and …

us (code pays fourni par la source)

350P Precision oncology insights: Mapping germline BRCA testing protocols for PARP inhibitor intervention in HER2 negative advanced breast cancer

Sobia Kanwal, Sarah Khan, Harold Nathan Tan, Mohammed Q. Al‐Ani et autres

85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC)

K-L. Koster, A.S.D.F.M. Parreira, Harold Nathan Tan, Athanasios Zachariou et autres

gb (code pays fourni par la source)